



## Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

September 5, 2025

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

Individuals interested in listening to the live conference call may do so through this [webcast link](#) or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 4762775. A webcast replay will be available from the "Investors" section of the Company's website [here](#) for 90 days following the completion of the call.

### **About Rapport Therapeutics**

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

### **Contact**

Julie DiCarlo  
Head of Communications & IR  
Rapport Therapeutics  
[jdicarlo@rapportrx.com](mailto:jdicarlo@rapportrx.com)